Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has provided an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC) regarding the implementation of the H Share Full Circulation for 25,421,196 domestic shares. This marks a significant step in the company’s plan to enhance its market liquidity and investor accessibility. While the details of the implementation plan and conversion are yet to be finalized, the company will continue to update stakeholders on the progress, ensuring compliance with regulatory requirements. This move is expected to strengthen the company’s position in the biopharmaceutical sector and potentially attract more investors.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company is involved in the development and production of biopharmaceutical products, with a focus on expanding its market presence through strategic initiatives such as the H Share Full Circulation.
YTD Price Performance: 90.69%
Average Trading Volume: 420,028
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$68.64B
See more insights into 6990 stock on TipRanks’ Stock Analysis page.